Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Patricia N Sidharta,1 Meggane Melchior,1 Martin K Kankam,2 Jasper Dingemanse1 1Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil CH-4123, Switzerland; 2Vince and Associates Clinical Research, Overland Park, KS 66211, USA Background: Aprocitentan is an orally active, dual...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Sidharta PN, Melchior M, Kankam MK, Dingemanse J
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Dove Medical Press 2019-03-01
Rangatū:	Drug Design, Development and Therapy
Ngā marau:	First-in-human study endothelin endothelin receptor antagonist aprocitentan pharmacokinetics pharmacodynamics
Urunga tuihono:	https://www.dovepress.com/single--and-multiple-dose-tolerability-safety-pharmacokinetics-and-pha-peer-reviewed-article-DDDT
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!